Subsequent Event |
9 Months Ended | ||
|---|---|---|---|
Sep. 30, 2011 | |||
| Subsequent Event | |||
| Subsequent Event |
On November 4, 2011, the Company announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder ("MDD"). The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5mg and 5mg, to placebo over an 8-week treatment period. Results from the study did not demonstrate Serdaxin's efficacy compared to placebo measured by the Montgomery-Asberg Depression Rating Scale ("MADRS"). All groups showed an approximate 14 point improvement in the protocol defined primary endpoint of MADRS. All groups had a substantial number of patients who demonstrated a meaningful clinical improvement from baseline. The study showed Serdaxin to be safe and well tolerated. The Company is currently evaluating future plans for its candidate pipeline as well as allocations of resources for the candidates.
|